香港大学Cancer Res发文:通过CRISPR-Cas
Ebiotrade,
【字体: 大 中 小 】 时间:2022年01月13日 来源:The University of Hong Kong 编辑推荐: 一个研究小组已经成功地将一种经批准的血管扩张药伊芬普地尔与FDA批准的一线药物索拉非尼联合用于肝细胞癌(HCC)治疗。本研究利用…
【字体: 大 中 小 】 时间:2022年01月13日 来源:The University of Hong Kong 编辑推荐: 一个研究小组已经成功地将一种经批准的血管扩张药伊芬普地尔与FDA批准的一线药物索拉非尼联合用于肝细胞癌(HCC)治疗。本研究利用…
A research team of LKS Faculty of Medicine, The University of Hong Kong (HKUMed) has successfully repurposed an approved drug…
A research team of LKS Faculty of Medicine, The University of Hong Kong (HKUMed) has successfully repurposed an approved drug…
A research team of LKS Faculty of Medicine, The University of Hong Kong (HKUMed) has successfully repurposed an approved drug…
A research team of LKS Faculty of Medicine, The University of Hong Kong (HKUMed) has successfully repurposed an approved drug…
A research team has successfully repurposed an approved drug ifenprodil, a vasodilator, to be used in combination with the FDA-ap…
A research team of LKS Faculty of Medicine, The University of Hong Kong (HKUMed) has successfully repurposed an approved drug…
Credit: The University of Hong Kong A research team of LKS Faculty of Medicine, The University of Hong Kong (HKUMed) has…
Credit: The University of Hong Kong A research team of LKS Faculty of Medicine, The University of Hong Kong (HKUMed) has…
. The research team includes (from left): Dr Stephanie Ma, Associate Professor; Dr Xu Feng, Post-doctoral Fellow; Dr Carol Tong…